Patents by Inventor Paul J. Conlon, III

Paul J. Conlon, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5484887
    Abstract: Interleukin 1 has been purified by use of various techniques including ion exchange chromatography and dye-ligand affinity chromatography. By these techniques, interleukin 1 has been purified to homogeneity. The high purification of interleukin 1 has enabled the amino acid composition of this protein to be ascertained and its amino acid sequence to be partially determined.
    Type: Grant
    Filed: November 30, 1984
    Date of Patent: January 16, 1996
    Assignee: Immunex Corporation
    Inventors: Shirley R. Kronheim, Carl J. March, Paul J. Conlon, III, Thomas P. Hopp
  • Patent number: 5122459
    Abstract: Double-stranded cDNA is prepared from polyadenylated RNA extracted from activated human peripheral blood adherent mononuclear cells. The cDNA is inserted within a plasmid vector and then the recombinant plasmid employed to transform an appropriate host. Transformed hosts are identified and grouped into pools. Plasmid DNA prepared from these pools is hybridized with a labeled, synthetic oligonucleotide probe corresponding to a portion of the amino acid sequence of the interleukin 1 protein. Pools of host cells that provide a positive signal to the probe are identified, plated out and then employed in direct bacterial colony hybridization with the same probe, thereby to isolate the particular positive colony. Plasmid DNA is prepared from this colony and characterized by restriction enzyme mapping and sequencing by chain-termination method. The coding region for the IL-1 gene is inserted into a shuttle vector for amplification of the vector followed by expression of functional IL-1.
    Type: Grant
    Filed: November 30, 1989
    Date of Patent: June 16, 1992
    Assignee: Immunex Corporation
    Inventors: Paul J. Conlon, III, David j. Cosman, Kenneth H. Grabstein, Thomas P. Hopp, Shirley R. Kronheim, Alf D. Larsen, Carl J. March, Virginia L. Price, Douglas P. Cerretti
  • Patent number: 5078996
    Abstract: Macrophages and precursor monocytes are activated to exhibit tumoricidal activity by stimulation solely with granulocyte-macrophage colony stimulating factor. A patient suffering from tumors can be treated by direct administration of therapeutically effective quantities of activated granulocyte-macrophage colony stimulating factor. Homogeneous granulocyte-macrophage colony stimulating factor for use in activating macrophages and monocyte precursors is prepared by recombinant DNA techniques. The gene coding for granylocyte-macrophage colony stimulating factor is isolated and then recombinant protein product expressed in an appropriate expression system. The granulocyte-macrophage colony stimulating factor recovered from the expression system is purified to homogeneity by reverse phase high-performance liquid chromatography.
    Type: Grant
    Filed: July 31, 1986
    Date of Patent: January 7, 1992
    Assignee: Immunex Corporation
    Inventors: Paul J. Conlon, III, Kenneth H. Grabstein
  • Patent number: 4782137
    Abstract: A hybrid polypeptide composed of an identification peptide and a desired functional protein are produced by recombinant DNA techniques. A DNA expression vector is constructed that includes segments of DNA coding for the identification peptide and the desired functional protein. The identification peptide consists of a highly antigenic N-terminal portion and a C-terminal linking portion that connects the identification peptide to the N-terminal of the functional protein. The linking portion of the identification peptide is cleavable at a specific amino acid residue adjacent the functional protein by use of a sequence specific proteolytic enzyme or chemical proteolytic agent. The hybrid polypeptide expressed by the host cells transformed by the cloning vector is removed therefrom and purfied by affinity chromatography techniques by use of an immobilized ligand specific to the antigenic portion of the identification peptide.
    Type: Grant
    Filed: July 23, 1987
    Date of Patent: November 1, 1988
    Assignee: Immunex Corporation
    Inventors: Thomas P. Hopp, Susan L. Bektesh, Paul J. Conlon, III, Carl J. March
  • Patent number: 4703004
    Abstract: A hybrid polypeptide composed of an identification peptide and a desired functional protein are produced by recombinant DNA techniques. A DNA expression vector is constructed that includes segments of DNA coding for the identification peptide and the desired functional protein. The identification peptide consists of a highly antigenic N-terminal portion and a C-terminal linking portion that connects the identification peptide to the N-terminal of the functional protein. The linking portion of the identification peptide is cleavable at a specific amino acid residue adjacent the functional protein by use of a sequence specific proteolytic enzyme or chemical proteolytic agent. The hybrid polypeptide expressed by the host cells transformed by the cloning vector is removed therefrom and purified by affinity chromatography techniques by use of an immobilized ligand specific to the antigenic portion of the identification peptide.
    Type: Grant
    Filed: January 24, 1984
    Date of Patent: October 27, 1987
    Assignee: Immunex Corporation
    Inventors: Thomas P. Hopp, Susan L. Bektesh, Paul J. Conlon, III, Carl J. March
  • Patent number: 4658018
    Abstract: Colony stimulating factor derived from malignant cells has been purified by use of various techniques including multiple high performance liquid chromotography steps. By this technique, colony stimulating factor has been resolved into distinct species, and one of the species denominated as CSF-2A, has been purified to homogeneity. The high purification of the CSF-2A has enabled the amino acid composition of this protein molecule to be partially sequenced with an automated sequencer.
    Type: Grant
    Filed: March 13, 1984
    Date of Patent: April 14, 1987
    Assignee: Immunex Corporation
    Inventors: David L. Urdal, Carl J. March, Diane Y. Mochizuki, Paul J. Conlon, III